AKT1 and breast carcinoma: Our results demonstrating that BI-D1870 enhances the response to the Akt inhibitor ipatasertib in PM cells appear promising and are in line with data showing chemo- and radiosensitizing effects in colon and breast cancer cells by combined inhibition of RSK and Akt [56, 57].